<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092961</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00004Sub</org_study_id>
    <nct_id>NCT02092961</nct_id>
  </id_info>
  <brief_title>Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study</brief_title>
  <acronym>OSKIRA 4 SS</acronym>
  <official_title>A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Russia: Public Health Institute</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative
      and more sensitive modalities for measuring the beneficial effects of syk inhibition with
      fostamatinib in patients with active RA. This MRI sub-study was reported later than the main
      study due to recruitment delays at specialist imaging sites and so is registered and
      presented entirely separately to the main study results.

      This study will investigate the impact of treatment on joint activity and damage by
      assessing synovitis, osteitis, bone erosions and joint space narrowing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sub-study to OSKIRA-4: A Phase IIB, Multi-Centre, Randomised, Double-Blind,
      Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium
      Monotherapy Compared with Placebo or Adalimumab Monotherapy in Patients with Active
      Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study Date: 21 March 2011 Version: 1
      Primary objective: Assess the efficacy of fostamatinib in reducing joint synovial disease
      activity as measured by: - Change from baseline to Week 6 (versus placebo) in OMERACT RAMRIS
      synovitis score.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to
    Rigel Pharmaceuticals.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>OMERACT RAMRIS synovitis score at week 6</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) synovitis score using Contrast-Enhanced MRI (CE-MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT RAMRIS synovitis score at week 24</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) synovitis score using Contrast-Enhanced MRI (CE-MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT RAMRIS osteitis score</measure>
    <time_frame>Baseline, 6 Weeks and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) osteitis score using Contrast-Enhanced MRI (CE-MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of structural joint damage as measured by OMERACT RAMRIS erosion score and joint space narrowing</measure>
    <time_frame>Baseline, 6 Weeks and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) erosion score using Contrast-Enhanced MRI (CE-MRI)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Dosing Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment and subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral treatment and subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib plus placebo injections</intervention_name>
    <description>Fostamatinib 100mg twice daily and placebo injection once every two weeks</description>
    <arm_group_label>Dosing Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab and placebo of fostamatinib</intervention_name>
    <description>Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks, plus placebo to fostamatinib twice daily.</description>
    <arm_group_label>Dosing Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of fostamatinib, fostamatinib, and placebo injections</intervention_name>
    <description>Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.</description>
    <arm_group_label>Dosing Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Male or female aged 18 and over - Active rheumatoid arthritis (RA)
        diagnosed after the age of 16 and diagnosis within 5 years prior to study visit 1 and
        inadequate response to treatment with a maximum 2 Disease-Modifying anti-rheumatic drug
        (DMARD) therapies, or diagnosis within 5 years prior to study visit 1 and intolerance to
        DMARD therapy, or diagnosis within 2 years prior to study visit 1 and no previous use of
        DMARDs - 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint
        count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or
        C-Reactive Protein (CRP) blood result of 10mg/L or more - At least 2 of the following:
        documented history or current presence of positive rheumatoid factor (blood test),
        radiographic erosion within 12 months prior to study enrolment, presence of serum
        anti-cyclic citrullinated peptide antibodies (blood test) Presence of at least one swollen
        hand or wrist joint. Presence of synovitis on baseline MRI scan, defined as at least 1
        joint with RAMRIS synovitis score of +1 or greater.  Exclusion Criteria: - Females who are
        pregnant or breast feeding - Poorly controlled hypertension - Liver disease or significant
        liver function test abnormalities - Certain inflammatory conditions (other than rheumatoid
        arthritis), connective tissue diseases or chronic pain disorders - Recent or significant
        cardiovascular disease - Significant active or recent infection including tuberculosis -
        Previously received treatment with a TNF alpha antagonist (including etanercept,
        certolizumab, adalimumab, infliximab, golimumab) or anakinra or previous treatment with
        other biological agent including rituximab, abatacept and tocilizumab - Use of any DMARDs
        within 6 weeks before first study visit - Severe renal impairment - Neutropenia Unable to
        undergo an MRI examination (e.g. presence of a pacemaker, defibrillator, or other
        implanted metallic device such as anterior interbody cages, aneurysm clip or pedicle
        screws). Known allergy to Gadolinium-based contrast agent,  tattoos [in area of
        examination if contains metallic pigment], Likely to require sedation for the procedure.
        eGFR less than 55 mL/min
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil MacKillop, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonf√ºred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stellenbosch</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>OSKIRA</keyword>
  <keyword>fostamatinib</keyword>
  <keyword>CE-MRI</keyword>
  <keyword>DCE-MRI</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
